PE20070325A1 - Formas de dosificacion oral que comprenden compuestos derivados de carbamato - Google Patents
Formas de dosificacion oral que comprenden compuestos derivados de carbamatoInfo
- Publication number
- PE20070325A1 PE20070325A1 PE2006000742A PE2006000742A PE20070325A1 PE 20070325 A1 PE20070325 A1 PE 20070325A1 PE 2006000742 A PE2006000742 A PE 2006000742A PE 2006000742 A PE2006000742 A PE 2006000742A PE 20070325 A1 PE20070325 A1 PE 20070325A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- oral dosage
- compounds
- compound
- dosage forms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000006186 oral dosage form Substances 0.000 title abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical compound C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION ORAL QUE COMPRENDE UN COMPUESTO DE FORMULA (I) O UN COMPUESTO DE FORMULA (II), DONDE X ES UN HALOGENO; R1, R2, R3, R4, R5 Y R6 SON H O ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON FENILO QUE ESTA OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4), NH, NITRO O CN; DICHOS COMPUESTOS COMPRENDEN ENANTIOMEROS DE FORMULA (Ia), (IIa), ENTRE OTROS, O MEZCLAS RACEMICAS DE LOS MISMOS, EN DONDE PREDOMINA UN ENANTIOMERO EN UNA CANTIDAD DE 90%. SE REFIERE TAMBIEN A UNA ESTRUCTURA DE DOSIFICACION ORAL DE LIBERACION SOSTENIDA QUE LIBERA DE MODO SOSTENIDO EL COMPUESTO DE FORMULA (I) O (II) A VELOCIDADES QUE PROVEEN UNA CONCENTRACION PLASMATICA MAXIMA PROMEDIO DE DOSIS UNICA Cmax DEL COMPUESTO DE FORMULA (I) O (II), QUE SATISFACEN LA RELACION 5ng/ml/mg £ Cmax £ 16ng/ml/mg; Y DISPOSITIVOS QUE PERMITAN UNA DOSIFICACION DE DICHOS COMPUESTOS DE MODO QUE REDUZCA SUS EFECTOS SECUNDARIOS. LA CANTIDAD LIBERADA DE LOS COMPUESTOS DE LA FORMA DE DOSIFICACION ORAL A LAS 2 HORAS ES DE 10% EN PESO DE LA DOSIS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CONVULSIONES, EPILEPSIA, ATAQUE APOPLEJICO, ESPASMO MUSCULAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69571505P | 2005-06-29 | 2005-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070325A1 true PE20070325A1 (es) | 2007-05-12 |
Family
ID=37310173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000742A PE20070325A1 (es) | 2005-06-29 | 2006-06-27 | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070004797A1 (es) |
| EP (1) | EP1898885A1 (es) |
| AR (1) | AR054524A1 (es) |
| CA (1) | CA2613933A1 (es) |
| PE (1) | PE20070325A1 (es) |
| TW (1) | TW200740429A (es) |
| WO (1) | WO2007002906A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
| US20090274759A1 (en) * | 2005-06-03 | 2009-11-05 | Egalet A/S | Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| EP2104493A2 (en) * | 2007-01-16 | 2009-09-30 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
| US20080292692A1 (en) * | 2007-05-21 | 2008-11-27 | Shira Pilch | Impermeable Capsules |
| AU2008258596B2 (en) * | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| US10736850B2 (en) * | 2007-08-13 | 2020-08-11 | Ohemo Life Sciences Inc. | Abuse resistant oral opioid formulations |
| AU2010206376B2 (en) * | 2009-01-26 | 2012-10-18 | Egalet Ltd. | Controlled release formulations with continuous efficacy |
| ES2607209T3 (es) * | 2009-02-06 | 2017-03-29 | Egalet Ltd. | Composiciones farmacéuticas resistentes al abuso |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| CN103717210B (zh) * | 2011-06-15 | 2018-04-13 | 友霖生技医药股份有限公司 | 多层式胶囊及其制造方法 |
| EA201590165A1 (ru) | 2012-07-06 | 2015-08-31 | Эгалет Лтд. | Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения |
| WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| WO2002067926A1 (en) * | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating movement disorders |
| NZ553813A (en) * | 2004-09-16 | 2010-09-30 | Janssen Pharmaceutica Nv | Use of 2-phenyl-1, 2-ethanediol-(DI) carbamates for treating epileptogenesis and epilepsy |
-
2006
- 2006-06-27 PE PE2006000742A patent/PE20070325A1/es not_active Application Discontinuation
- 2006-06-28 AR ARP060102781A patent/AR054524A1/es not_active Application Discontinuation
- 2006-06-28 TW TW095123239A patent/TW200740429A/zh unknown
- 2006-06-29 CA CA002613933A patent/CA2613933A1/en not_active Abandoned
- 2006-06-29 WO PCT/US2006/025692 patent/WO2007002906A1/en not_active Ceased
- 2006-06-29 US US11/478,241 patent/US20070004797A1/en not_active Abandoned
- 2006-06-29 EP EP06786031A patent/EP1898885A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1898885A1 (en) | 2008-03-19 |
| AR054524A1 (es) | 2007-06-27 |
| US20070004797A1 (en) | 2007-01-04 |
| WO2007002906A1 (en) | 2007-01-04 |
| TW200740429A (en) | 2007-11-01 |
| CA2613933A1 (en) | 2007-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070325A1 (es) | Formas de dosificacion oral que comprenden compuestos derivados de carbamato | |
| PE20060285A1 (es) | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) | |
| AR052156A1 (es) | Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos | |
| PE20040832A1 (es) | Derivados de indolil pirazinona | |
| PE20110215A1 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| PE20060842A1 (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
| PE20050484A1 (es) | Composicion farmaceutica de liberacion sostenida | |
| PE20110152A1 (es) | Nuevos derivados de sulfamida sustituida | |
| AR061066A1 (es) | Coterapeutica para el tratamiento de epilepsia y trastornos relacionados | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| TW200508180A (en) | Therapeutic agents | |
| ES2173846T3 (es) | Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2. | |
| CO6382111A2 (es) | Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia | |
| AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
| PE20080929A1 (es) | Metodos para el tratamiento de la depresion | |
| AR035756A1 (es) | Uso de carbamatos en la preparacion de medicamentos para la prevencion o tratamiento de trastornos neurodegenerativos | |
| GT200300183A (es) | Nuevos agonistas ppar-alfa y ppar-gamma | |
| PE20120217A1 (es) | Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica | |
| MY133370A (en) | Carbamate compounds for use in preventing or treating bipolar disorders | |
| AR033427A1 (es) | Uso de compuestos carbamatos en el tratamiento del dolor | |
| PE20100737A1 (es) | Nuevos compuestos | |
| PT1408953E (pt) | Compostos carbamato para utilizacao na prevencao ou tratamento do disturbio bipolar | |
| MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
| ECSP088602A (es) | Compuestos con efectos medicinales debido a la interacción con el receptor de glucocorticoides | |
| PT1305082E (pt) | Compostos de carbamato para utilizacao na prevencao ou tratamento da dor neuropatica e dor associada a cefaleia de salvas e enxaqueca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |